Is Now Available


TREMFYA™ is a prescription medicine approved to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light or UV light).


TREMFYA™ is the first and only approved treatment to selectively block interleukin-23 (IL-23), one of the key proteins thought to be responsible for plaque psoriasis. Also, with one maintenance dose every eight weeks (after two starter doses at weeks 0 and 4) you don’t need to think about managing your treatment schedule for your moderate to severe plaque psoriasis while on TREMFYA™.

TREMFYA™ is brought to you by Janssen Biotech, Inc., a leader in providing treatments for plaque psoriasis.

TREMFYA™ is administered as a single 100 mg injection under the skin at weeks 0 and 4 and then every 8 weeks. It is administered by a healthcare provider or self-injected only after proper training.

Discover the immunological conditions that Janssen Immunology has expertise in treating, which include rheumatology, gastroenterology and dermatology.